| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Global Regulatory Affairs | VP of Us Regulatory & Fda Rel.
1 company
Miriam Provost last filed a Form 4 in December 2023, as VP, Global Regulatory Affairs at TMDX. Miriam Provost's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Miriam Provost's trades have earned a below-average insider score of 32/100 across 5 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -40.1%.
At the last filing, the largest reported position was 23,348 shares of TMDX. The TMDX filings lean toward selling, a net 18,635 shares.
Miriam Provost has 13 Form 4 filings on record from May 2019 to December 2023, all as VP, Global Regulatory Affairs at TransMedics Group (TMDX), 2019–2023.
The 30 reported transactions were 13 option exercises, 9 open-market sales, 4 option or other derivative awards and 2 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 5 sales worth about $1.1M.
The largest open-market sale was 4,122 shares of TMDX at an average $75.10 on December 13, 2023, about $310K. Twelve months later TMDX was down 14%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from December 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2023 | TMDX Transmedics Group, Inc. | VP, Global Regulatory Affairs | Sale+OE | 4,122 | $75.10 | $309,562.20 | -14.1% | +10.7% | -14.1% | |
| Aug 31, 2023 | TMDX Transmedics Group, Inc. | VP, Global Regulatory Affairs | Sale+OE | 2,708 | $66.52 | $180,136.16 | -10.3% | +11.0% | +156.1% | |
| Dec 13, 2022 | TMDX Transmedics Group, Inc. | VP, Global Regulatory Affairs | Sale+OE | 4,315 | $62.53 | $269,796.80 | -22.2% | +19.4% | +25.1% | |
| Dec 9, 2022 | TMDX Transmedics Group, Inc. | VP, Global Regulatory Affairs | Sale+OE | 3,613 | $59.00 | $213,167.00 | -21.0% | +31.4% | +24.0% | |
| Sep 15, 2021 | TMDX Transmedics Group, Inc. | VP of Us Regulatory & Fda Rel. | Sale+OE | 3,877 | $31.34 | $121,505.18 | -31.2% | -33.5% | +65.6% |